TY  - GEN
A1  - Tammen, Harald
A1  - Koemhoff, Martin
A1  - Mark, Michael
A1  - Hocher, Berthold
A1  - Delic, Denis
A1  - Hess, Rüdiger
A1  - von Eynatten, Maximilian
A1  - Klein, Thomas
T1  - Linagliptin treatment is associated with improved cobalamin (vitamin B-12) storage in mice and potentially in humans
T2  - Diabetologia : journal of the European Association for the Study of Diabetes (EASD)
Y1  - 2018
SN  - 0012-186X
SN  - 1432-0428
VL  - 61
SP  - S252
EP  - S253
PB  - Springer
CY  - New York
ER  - 
TY  - GEN
A1  - Schernthaner, G.
A1  - Groop, P.
A1  - Cooper, M.
A1  - Perkovic, V
A1  - Hocher, Berthold
A1  - Kanasaki, K.
A1  - Sharma, K.
A1  - Stanton, R.
A1  - Toto, R.
A1  - Cescutti, Jessica
A1  - Gordat, M.
A1  - Meinicke, T.
A1  - Koitka-Weber, A.
A1  - Woerle, H.
A1  - Eynatten, M.
T1  - EFFECTS OF LINAGLIPTIN ON GLYCAEMIC CONTROL AND ALBUMINURIA IN TYPE 2
DIABETES - THE MARLINA-T2D (TM) TRIAL
T2  - Nephrology
Y1  - 2016
U6  - https://doi.org/10.1111/nep.12887
SN  - 1320-5358
SN  - 1440-1797
VL  - 21
SP  - 60
EP  - 60
PB  - Wiley-Blackwell
CY  - Hoboken
ER  - 
TY  - GEN
A1  - Reichetzeder, Christoph
A1  - Hocher, Berthold
T1  - DPP4 inhibition prevents AKI
T2  - Oncotarget
KW  - acute kidney injury
KW  - DPP-4 inhibitors
KW  - ischemia reperfusion injury
KW  - gliptins
KW  - Dipeptidyl peptidase IV
Y1  - 2017
U6  - https://doi.org/10.18632/oncotarget.20212
SN  - 1949-2553
VL  - 8
SP  - 64655
EP  - 64656
PB  - Impact Journals LLC
CY  - Orchard Park
ER  - 
TY  - GEN
A1  - Hocher, Berthold
A1  - Zeng, Shufei
T1  - Clear the fog around parathyroid hormone assays
BT  - what do iPTH assays really measure?
T2  - Clinical journal of the American Society of Nephrology
KW  - Assays
KW  - Biological Assay
KW  - CKD
KW  - oxidative stress
KW  - PTH
Y1  - 2018
U6  - https://doi.org/10.2215/CJN.01730218
SN  - 1555-9041
SN  - 1555-905X
VL  - 13
IS  - 4
SP  - 524
EP  - 526
PB  - American Society of Nephrology
CY  - Washington
ER  - 
TY  - GEN
A1  - Hocher, Berthold
A1  - Zeng, Shufei
T1  - Need for better PTH assays for clinical research and patient treatment
T2  - Clinical chemistry and laboratory medicine : journal of the Forum of the European Societies of Clinical Chemistry - the European Branch of the International Federation of Clinical Chemistry and Laboratory Medicine
Y1  - 2017
U6  - https://doi.org/10.1515/cclm-2017-0617
SN  - 1434-6621
SN  - 1437-4331
VL  - 56
IS  - 2
SP  - 183
EP  - 185
PB  - De Gruyter
CY  - Berlin
ER  - 
TY  - GEN
A1  - Hocher, Berthold
A1  - Yin, Lianghong
T1  - Why Current PTH Assays Mislead Clinical Decision Making in Patients with Secondary Hyperparathyroidism
T2  - Nephron
N2  - Preclinical studies in cell culture systems as well as in whole animal chronic kidney disease (CKD) models showed that parathyroid hormone (PTH), oxidized at the 2 methionine residues (positions 8 and 18), caused a loss of function. This was so far not considered in the development of PTH assays used in current clinical practice. Patients with advanced CKD are subject to oxidative stress, and plasma proteins (including PTH) are targets for oxidants. In patients with CKD, a considerable but variable fraction (about 70 to 90%) of measured PTH appears to be oxidized. Oxidized PTH (oxPTH) does not interact with the PTH receptor resulting in loss of biological activity. Currently used intact PTH (iPTH) assays detect both oxidized and non-oxPTH (n-oxPTH). Clinical studies demonstrated that bioactive, n-oxPTH, but not iPTH nor oxPTH, is associated with mortality in CKD patients.
KW  - Serum intact-parathyroid hormone level
KW  - Dialysis patients
KW  - Mortality
Y1  - 2017
U6  - https://doi.org/10.1159/000455289
SN  - 1660-8151
SN  - 2235-3186
SN  - 0028-2766
VL  - 136
IS  - 2
SP  - 137
EP  - 142
PB  - Karger
CY  - Basel
ER  - 
TY  - GEN
A1  - Hocher, Berthold
A1  - Tsuprykov, Oleg
T1  - Renoprotective effects of GLP1R agonists and SGLT2 inhibitors
T2  - Nature reviews nephroloy
N2  - New data from the LEADER trial show that the glucagon-like peptide 1 receptor agonist liraglutide protects against diabetic nephropathy in patients with type 2 diabetes mellitus. The renoprotective efficacy of liraglutide is not, however, as great as that reported for the sodium-glucose cotransporter 2 inhibitor emplagiflozin in the EMPA-REG OUTCOME trial.
Y1  - 2017
U6  - https://doi.org/10.1038/nrneph.2017.140
SN  - 1759-5061
SN  - 1759-507X
VL  - 13
SP  - 728
EP  - 729
PB  - Nature Publ. Group
CY  - New York
ER  -